- Biogen pays $7.3B to acquire Reata and newly approved Skyclarys FiercePharma
- Biogen to buy rare-disease drugmaker Reata in $7.3B deal Yahoo Finance
- Biogen Stock: Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals Investor's Business Daily
- Biogen Deal for Reata Signals a Turn to Rare Diseases Bloomberg
- Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition Forbes
- View Full Coverage on Google News
Saturday, July 29, 2023
Biogen pays $7.3B to acquire Reata and newly approved Skyclarys - FiercePharma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment